Lantern Pharma Aktie
WKN DE: A2P5NM / ISIN: US51654W1018
|
03.12.2025 15:08:53
|
Lantern Pharma Reports Positive Phase 1a Data For LP-184 In Advanced Solid Tumors
(RTTNews) - Lantern Pharma Inc. (LTRN), a clinical-stage biotechnology company, on Wednesday shared additional details and clinical insights from its completed Phase 1a dose-escalation study of LP-184.
The trial showed encouraging, durable disease control in heavily pre-treated patients with advanced solid tumors, many of whom had DNA damage repair (DDR) pathway deficiencies. The study met all primary endpoints for safety and tolerability.
Lantern said it plans to advance LP-184 into multiple Phase 1b/2 trials.
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Lantern Pharma Inc Registered Shsmehr Nachrichten
| Keine Nachrichten verfügbar. |
Analysen zu Lantern Pharma Inc Registered Shsmehr Analysen
Aktien in diesem Artikel
| Lantern Pharma Inc Registered Shs | 3,54 | 2,02% |
|